Publication | Closed Access

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

ObesityMetabolic SyndromeDgat2 InhibitorHepatologyAcc InhibitorNonalcoholic Fatty Liver DiseaseLiver PhysiologyDiabetesPharmacologyPharmacotherapyRandomized Phase 2ALiver DiseaseFatty Liver DiseaseMedicineHealth Sciences